New vaccine may stop, slow Alzheimer's

Scientists at Oklahoma Medical Research Foundation are reporting success in advancing an experimental, preclinical vaccine that can prevent or slow Alzheimer's. The researchers, led by Dr. Jordan Tang, immunized mice engineered with Alzheimer's with the memapsin 2 protein, which plays a role in the development of plaque believed to be central to the memory-wasting disease. Human trials of the vaccine could be just a few years away, though scientists say that any successful vaccine approach would likely be used in combination with other therapies. Other companies, most notably Elan, have attempted to advance vaccines, but failed.

"What we saw is that the mice immunized with memapsin 2 developed 35 percent fewer plaques than their non-vaccinated counterparts," said Tang. "Those immunized mice also performed better than control mice in tests designed to assess their cognitive function."

- here's the release for more information
- read this report on the project

ALSO: Children with a gene known to increase the risk of Alzheimer's disease already show signs of reduced cognitive function, a study has found. Release

Related Articles:
Blood test accurate in identifying Alzheimer's. Report
Big pharma sees big payback for Alzheimer's research. Report
Study shows that Alzheimer's drugs don't work. Report
Researchers tout results for new Alzheimer's test. Report
BRNI discovery raises hopes for Alzheimer's test. Report

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.